Quest Diagnostics Inc vs Prologis Inc — how do they compare? Quest Diagnostics Inc trades at $230.31 (market cap $25.48B), while Prologis Inc trades at $128.93 (market cap $122.87B). The key difference: Prologis Inc is far larger — about 4.8× Quest Diagnostics Inc's market cap, and Prologis Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Prologis Inc for 102 Days on average.
| DGX | PLD | |
|---|---|---|
Market Cap | $25.48B | $122.87B |
Volume | 941,866 | 4,222,957 |
Sector | Health | Real Estate |
52-Week High | $247.45 | $149.96 |
52-Week Low | $173.49 | $111.23 |
Typical Hold Time | 56 Days | 102 Days |
Enterprise Value | $31.23B | $157.61B |
Dividend Yield | 1.49% | 3.31% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Prologis (PLD) trades at $127.3, down 1.07% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, supported by robust leasing activity and data center expansion, while profitability remains high with a net income margin of 45.79%. Analyst consensus is bullish with a $155.15 price target, though technical indicators show near-term pressure.
The outlook for PLD is positive due to its leading position in industrial real estate, driven by e-commerce and data center demand. Risks include rising debt levels and market volatility. Institutional buying and strong analyst support suggest long-term upside, but investors should monitor debt management and macroeconomic trends affecting REIT valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →